Analyses of all outcomes were conducted at the ICU level, followed
the intention-to-treat approach, and accounted for the
matched-pair design. All tests were 2-sidedwith 5%type I error.
For acquisition of either MRSA or VRE and other outcomes with
baseline period data,weighted paired t tests compared
changes inrates from baseline (prerandomization) to the
end of the study between the intervention and control ICUs.16
For outcomes without baseline period data, weighted paired
t tests compared study period rates or means between intervention
and control ICUs.16 Weighting accounted for differences in cluster sizes (eg, patient-time at risk) between ICUs
with each pair weighted according to the inverse variance of
the estimated effect size.33 Testing and estimation were performed
on the log scale to account for different ICU sizes34; estimated
rates and 95%confidence intervals were obtained by
exponentiating. A prespecified secondary analysis of the primary
outcome and key secondary outcomes was performed,
adjusting for ICU admission prevalence of MRSA or VRE. For
each pair, the weight was the inverse variance of the estimated
effect after adjusting for admission prevalence ofMRSA
or VRE. All weighted paired t tests had 9 degrees of
freedom. The statistical plan is in the Supplement.
Analyses of all outcomes were conducted at the ICU level, followedthe intention-to-treat approach, and accounted for thematched-pair design. All tests were 2-sidedwith 5%type I error.For acquisition of either MRSA or VRE and other outcomes withbaseline period data,weighted paired t tests comparedchanges inrates from baseline (prerandomization) to theend of the study between the intervention and control ICUs.16For outcomes without baseline period data, weighted pairedt tests compared study period rates or means between interventionand control ICUs.16 Weighting accounted for differences in cluster sizes (eg, patient-time at risk) between ICUswith each pair weighted according to the inverse variance ofthe estimated effect size.33 Testing and estimation were performedon the log scale to account for different ICU sizes34; estimatedrates and 95%confidence intervals were obtained byexponentiating. A prespecified secondary analysis of the primaryoutcome and key secondary outcomes was performed,adjusting for ICU admission prevalence of MRSA or VRE. Foreach pair, the weight was the inverse variance of the estimatedeffect after adjusting for admission prevalence ofMRSAor VRE. All weighted paired t tests had 9 degrees offreedom. The statistical plan is in the Supplement.
การแปล กรุณารอสักครู่..